Pharmaceutical Research and Development Executive specializing in Nonclinical Development for over 30 years. Began at Merck/MSD Research Laboratories serving in numerous roles over 20 years ultimately serving as Vice President/Head, Worldwide Safety Assessment responsible for all nonclinical aspects for potential drug development candidates, including toxicologic evaluation, defining preclinical drug development candidate plans, interacting with drug development teams, preparation of regulatory submissions including INDs/NDAs,. Subsequently, was Vice President, Exploratory Development at Vertex Pharmaceuticals responsible for all nonclinical development activities and Clinical Pharmacology directing programs through to proof of concept. While at Vertex, was member of management team responsible for first NCE developed within the Company.
Pharmaceutical Research and Development Executive who applies expertise in cancer biology and immune-oncology to the development of new classes of cancer medicines. She has led small molecule and biologics discovery programs and, currently, therapeutic vaccines. She is Senior Vice President of immuno-oncology at Genocea Biosciences. Her other positions have included Vice President of oncology discovery at Roche, Vice President of Janssen oncology innovation and founding head of research at the Belfer Institute for Applied Cancer Science at Dana Farber Cancer Institute, Harvard Medical School. Pam developed her drug discovery experience at Bristol Myers Squibb in applied genomics and Merck in oncology. Pam earned her B.A. in biology at St. Michael’s College in Vermont, a doctorate in cellular biology at Stony Brook University, and a post-doctorate in genetics at Stanford University.
University of Texas MD Anderson Cancer Center and Scientific Director of the Oncology Research for Biologics and Immunotherapy Translation (ORBIT) platform, which coordinates development and production of clinical immunotherapeutic antibodies based on novel targets and preclinical reagents originating at MD Anderson. He also has established an independent lab at MD Anderson, where his group studies the origins of the immunosuppressive tumor microenvironment and how it can be disrupted to facilitate immune-mediated tumor rejection. At Memorial Sloan-Kettering Cancer Center, Dr. Curran published several influential papers describing how T-cell co-stimulatory pathways could be modulated in tandem to mediate immunologic rejection of melanomas in mice. He detailed how combination blockade of the T-cell co-inhibitory receptors CTLA-4 and PD-1 promoted the rejection of a majority of murine melanomas an unprecedented result that prompted the Food and Drug Administration to make this the first approved immunotherapy antibody combination. In addition, his subsequent immunologic studies of 4-1BB agonist antibodies earned him the Society for the Immunotherapy of Cancer’s prestigious Presidential Award.